AVANADE
7.9.2021 11:24:14 CEST | Business Wire | Press release
Avanade , the leading digital innovator on the Microsoft ecosystem, today announced the launch of its business in the United Arab Emirates (UAE), with offices in Dubai and Abu Dhabi. Adriano Neves, Avanade’s Sales, Industry and Client Relationships Lead in Brazil, has been appointed to lead the company’s newest entity and will relocate from São Paulo to Dubai.
Established by Accenture and Microsoft in 2000, Avanade today has 49,000 professionals globally focused on the Microsoft ecosystem providing technology and consulting expertise to help clients from across industries including financial services, oil and gas, and citizen services. Avanade’s presence in the United Arab Emirates represents the 26th country location in the company’s expanding global footprint.
Leveraging its global delivery network, technical depth and Microsoft-focused capabilities, Avanade will work with Accenture to jointly help clients in the UAE create exceptional experiences, build operational resilience and reimagine new business models. In the recently published “IDC MarketScape: Worldwide Microsoft Implementation Services 2021 Vendor Assessment ,” Accenture and Avanade have been jointly recognized as a leader based on current capabilities and future strategies. Together, Accenture and Avanade have been named Microsoft Global Alliance SI Partner of the Year 16 times , more than any other partner.
Adriano Neves, Avanade’s United Arab Emirates regional lead, said: “As organizations renew for the future, we want to make a positive impact in the region by helping our clients solve complex business problems that are unique to their industries and realize their business goals faster on the Microsoft platform.”
Nadya Abdulla Kamali, Accenture’s country managing director for the UAE, said: “We are thrilled to welcome Avanade to the United Arab Emirates. With our combined service capabilities, global scale and joint solution development on the Microsoft platform, we look forward to helping our clients drive an end-to-end digital transformation of their businesses.”
Sayed Hashish, General Manager, Microsoft UAE added: “Our partnership with Accenture through Avanade has grown tremendously, and the launch of Avanade in the United Arab Emirates marks another milestone for our successful collaboration. Together with Avanade and Accenture, we will continue to empower every person and organization in the UAE to achieve more.”
To fuel the company’s ambitious growth, Avanade is recruiting digital, IT and consulting specialists who have a passion for Microsoft platform technologies. Interested individuals are encouraged to apply for open roles here: https://www.avanade.com/en/career
About Adriano Neves, United Arab Emirates Regional Lead, Avanade
Based in Dubai, Adriano Neves leads a team of digital professionals focused on powering the Accenture Microsoft Business Group and helping enterprises realize business outcomes on the Microsoft platform. Prior to his current role, Adriano was responsible for Avanade’s Sales, Industry and Client Relationships in Brazil focused on delivering exceptional experiences and making a genuine human impact for clients. As one of Avanade’s first employees in Brazil, Adriano played a pivotal role in partnering with Accenture and Microsoft to not only establish Avanade’s business and market presence in the region, but to build the most relevant Microsoft partner in the region. Before he joined Avanade, Adriano spent nearly 10 years in a variety of leadership roles at Microsoft Brazil. In his spare time, Adriano volunteers as a business advisor to startups.
About Accenture
Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 569,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at www.accenture.com .
About Avanade
Avanade is the leading provider of innovative digital and cloud services, business solutions and design-led experiences on the Microsoft ecosystem. Our professionals bring bold, fresh thinking combined with technology, business and industry expertise to help make a genuine human impact for our clients, their customers and their employees. We are the power behind the Accenture Microsoft Business Group, helping companies to engage customers, empower employees, optimize operations and transform products, leveraging the Microsoft platform. Avanade has 49,000 professionals in 26 countries, bringing clients our best thinking through a collaborative culture that honors diversity and reflects the communities in which we operate. Majority owned by Accenture, Avanade was founded in 2000 by Accenture LLP and Microsoft Corporation. Learn more at www.avanade.com .
About Microsoft
Microsoft (Nasdaq “MSFT” @microsoft) enables digital transformation for the era of an intelligent cloud and an intelligent edge. Its mission is to empower every person and every organization on the planet to achieve more.
*Source : AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20210907005412/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom